(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/115452 A2

(51) International Patent Classification[7]: A61K 39/395, C07K 16/46

(21) International Application Number: PCT/US2005/012798

(22) International Filing Date: 15 April 2005 (15.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/562,804	16 April 2004 (16.04.2004)	US
60/582,045	21 June 2004 (21.06.2004)	US
60/582,044	21 June 2004 (21.06.2004)	US
60/654,713	18 February 2005 (18.02.2005)	US

(71) Applicant *(for all designated States except US)*: **MACROGENICS, INC.** [US/US]; 1500 East Gude Drive, Rockville, MD 20850-5307 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KOENIG, Scott** [US/US]; 10901 Ralston Road, Rockville, MD 20852 (US). **VERI, Maria, Concetta** [IT/US]; 7715 Good Fellow Way, Denwood, MD 20855 (US). **TUAILLON, Nadine** [US/US]; 912 Good Intent Road, Gettysburg, PA 17325 (US). **BONVINI, Ezio** [US/US]; 2 Shetland Court, Rockville, MD 20851 (US). **STAVENHAGEN, Jeffrey** [US/US]; 19417 Treadway Road, Brookville, MD 20833 (US). **RANKIN, Christopher** [US/US]; 12656 Piedmont Trail Road, Clarksburg, MD 20871 (US).

(74) Agents: **BRIVANLOU, Margaret, B.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *without international search report and to be republished upon receipt of that report*

(48) Date of publication of this corrected version: 6 April 2006

(15) Information about Correction: see PCT Gazette No. 14/2006 of 6 April 2006

[Continued on next page]

(54) Title: FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF



(57) Abstract: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

WO 2005/115452 A2

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.